Diagnosed in more than 90% of cervical cancers, the fourth deadliest cancer in women,
human papillomavirus (HPV) is currently the most common pathogen responsible for female …

In the 20th century, the development, licensing and implementation of vaccines as part of
large, systematic immunization programs started to address health inequities that existed …

Abstract The American Cancer Society (ACS) recommends that individuals with a cervix
initiate cervical cancer screening at age 25 years and undergo primary human …

This article provides an update on the global cancer burden using the GLOBOCAN 2020
estimates of cancer incidence and mortality produced by the International Agency for …

Viral infections contribute as a cause of 15–20% of all human cancers. Infection by
oncogenic viruses can promote different stages of carcinogenesis. Among many types of …

Background Human papillomavirus (HPV) immunisation with a bivalent vaccine (Cervarix)
was introduced in England, UK, in Sept 1, 2008: routine vaccination was offered to girls …

Background Funding for human papillomavirus (HPV) vaccination in Japan began in 2010
for girls aged 12–16 years, with three-dose coverage initially reaching more than 70%. On …

Abstract The American Cancer Society (ACS) presents an adaptation of the current Advisory
Committee on Immunization Practices recommendations for human papillomavirus (HPV) …

Background High-risk human papillomavirus causes cervical cancer. Vaccines have been
developed that significantly reduce the incidence of preinvasive and invasive disease. This …

Abstract The World Health Organization (WHO) advocates population-based screening
programs to reduce the global incidence of cervical cancer. However, screening guidelines …